Title:
BISPECIFIC ANTIBODY BINDING TO TNFR2 AND 4-1BB
Document Type and Number:
WIPO Patent Application WO/2024/037626
Kind Code:
A1
Abstract:
The present invention provides a bispecific antibody comprising: (a) a first antibody that specifically binds to a first antigen or an antigen-binding fragment thereof; and (b) a second antibody specifically binding to a second antigen or an antigen-binding fragment thereof, wherein the first antigen is TNFR2, and the second antigen is 4-1BB, or the first antigen is 4-1BB, and the second antigen is TNFR2.
Inventors:
ZHOU JINHUA (CN)
WU CHONGBING (CN)
JIANG XIAOLING (CN)
YIN LIUSONG (CN)
WU CHONGBING (CN)
JIANG XIAOLING (CN)
YIN LIUSONG (CN)
Application Number:
PCT/CN2023/113758
Publication Date:
February 22, 2024
Filing Date:
August 18, 2023
Export Citation:
Assignee:
SHENGHE CHINA BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
A61K39/395; A61P35/00; A61P35/02; A61P35/04; A61P37/02; C07K16/46; C12N15/13
Domestic Patent References:
| WO2022161425A1 | 2022-08-04 |
Foreign References:
| US20180194862A1 | 2018-07-12 | |||
| US20200270355A1 | 2020-08-27 | |||
| CN112794904A | 2021-05-14 | |||
| CN112969476A | 2021-06-15 | |||
| CN110291108A | 2019-09-27 |
Other References:
WANG LUYAO, WEI ZHENHUA, XIONG WEIJIA, BAI SUHANG, YU CHANGYUAN, YANG ZHAO: "Bispecific antibodies in clinical tumor therapy", CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 37, no. 2, 25 February 2021 (2021-02-25), pages 513 - 529, XP093139581, ISSN: 1872-2075, DOI: 10.13345/j.cjb.200327
Download PDF: